Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.
暂无分享,去创建一个
P. Koduru | K. Raju | V. Vadmal | G. Menezes | S. Shah | M. Susin | J. Kolitz | J. Broome | K Raju | P R Koduru | V Vadmal | G Menezes | S Shah | M Susin | J Kolitz | J D Broome | K. Raju | Shefali Shah | Geetha Menezes | Veena Vadmal
[1] W. Wilson,et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. , 1997, Blood.
[2] B. Karlan,et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. , 1996, Oncogene.
[3] O. Halevy,et al. Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment , 1989, Molecular and cellular biology.
[4] S. Sen,et al. p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro. , 1995, Cancer genetics and cytogenetics.
[5] R. Berger,et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. , 1991, Blood.
[6] V. Rotter,et al. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. , 1994, Blood.
[7] A. Giordano,et al. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest. , 1995, Blood.
[8] A. Levine,et al. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] W. Chan,et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.
[10] N. Nissen,et al. Follicular low‐grade non‐Hodgkin's lymphoma: Long‐term outcome with or without tumor progression , 1989, European journal of haematology.
[11] p53 mutations are associated with histologic transformation of follicular lymphoma , 1993 .
[12] M. Hsiao,et al. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. , 1994, Blood.
[13] S. Lowe,et al. p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.
[14] T. Colby,et al. Histologic conversion in the non-Hodgkin's lymphomas. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Minden,et al. Mutation of the p53 gene in human acute myelogenous leukemia. , 1991, Blood.
[16] Bert Vogelstein,et al. p53 function and dysfunction , 1992, Cell.
[17] F. Cabanillas,et al. Chromosome 17p and p53 changes in lymphoma , 1991, British journal of haematology.
[18] Ulrich Siebenlist,et al. Structure of the human immunoglobulin μ locus: Characterization of embryonic and rearranged J and D genes , 1981, Cell.
[19] M. Piris,et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. , 1994, British Journal of Cancer.
[20] T. Waldmann,et al. Human immunoglobulin κ light-chain genes are deleted or rearranged in λ-producing B cells , 1981, Nature.
[21] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[22] W. Velasquez,et al. Frequent nonrandom chromosome abnormalities in 27 patients with untreated large cell lymphoma and immunoblastic lymphoma. , 1988, Cancer research.
[23] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[24] M. Oken,et al. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.
[25] C. Osborne,et al. Histologic progression in non-Hodgkin's lymphoma. , 1982, Blood.
[26] T. Soussi,et al. Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. , 1994, The EMBO journal.
[27] M. Ewen,et al. p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. , 1995, Genes & development.
[28] N. Berinstein,et al. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. , 1994, Blood.
[29] D. Housman,et al. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[30] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[31] C. Bartram,et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. , 1993, Blood.
[32] M. Du,et al. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. , 1995, Blood.
[33] D C Louie,et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). , 1995, Blood.
[34] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[35] D. Pim,et al. Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.
[36] C. Bloomfield,et al. Sequential karyotypes in non‐Hodgkin lymphoma: Their nature and significance , 1990, Genes, chromosomes & cancer.
[37] 上田 宏之. Functional inactivation but not structural mutation of p53 causes liver cancer , 1995 .
[38] M. Ladanyi,et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non‐Hodgkin's lymphoma: Correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment , 1991, Genes, chromosomes & cancer.
[39] Carl W. Miller,et al. Human p53 gene localized to short arm of chromosome 17 , 1986, Nature.
[40] C. Osborne,et al. An autopsy study of histologic progression in non‐Hodgkin's lymphomas 192 cases from the national cancer institute , 1983, Cancer.
[41] C. Guillouf,et al. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. , 1995, Oncogene.
[42] F. Bosch,et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.
[43] M. Isobe,et al. Localization of gene for human p53 tumour antigen to band 17p13 , 1986, Nature.
[44] Elisa T. Lee,et al. Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.
[45] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[46] K. Offit,et al. Intermediate- to high-grade histology of lymphomas carrying t(14;18) is associated with additional nonrandom chromosome changes. , 1987, Blood.
[47] D. Weisenburger,et al. Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14;18)(q32;q21). , 1988, Journal of the National Cancer Institute.
[48] T. Rabbitts,et al. Chromosomal translocations in human cancer , 1994, Nature.
[49] D. Lane,et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.
[50] T. Waldmann,et al. Clustered arrangement of immunoglobulin λ constant region genes in man , 1981, Nature.
[51] H. Kaneko,et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.
[52] M. Piris,et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. , 1993, Blood.
[53] M. Kastan,et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[54] Wei Zhang,et al. P53 gene mutations in acute myelogenous leukaemia , 1992, British journal of haematology.
[55] H. Koeffler,et al. p53 in hematologic malignancies. , 1994, Blood.
[56] D. Longo,et al. p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.
[57] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[58] H. Saito,et al. Mutations of the p53 gene in B-cell lymphoma. , 1993, Leukemia & lymphoma.
[59] L. Cro,et al. Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. , 1994, Blood.
[60] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[61] G. Gaidano,et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[62] M. Key,et al. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[63] T. Waldmann,et al. Clustered arrangement of immunoglobulin lambda constant region genes in man. , 1981, Nature.
[64] K. Offit,et al. Molecular analysis of breaks in BCL-1 proto-oncogene in B-cell lymphomas with abnormalities of 11q13. , 1989, Oncogene.
[65] R. Collins,et al. Malignant lymphomas of follicular center cell origin in humans. V. incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma , 1984, Cancer.
[66] J. Milner. The role of p53 in the normal control of cell proliferation. , 1991, Current opinion in cell biology.
[67] E. Cesarman,et al. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. , 1994, The American journal of pathology.
[68] K. Offit,et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. , 1992, Blood.
[69] B. Quesnel,et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.